Table 2 Relationship between EGFR, K-Ras mutations and clinical characteristics of lung ASC patients.

From: Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods

Characteristics

No. of patients (%) Total 56

EGFR Mutation

K-Ras Mutation

+

−

P

+

−

P

31

25

4

52

Age

   

0.044

  

0.353

 ≥70

17 (30.4%)

6

11

 

2

15

 

 <70

39 (69.6%)

25

14

 

2

37

 

Gender

   

0.004

  

0.201

 Female

18 (32.1%)

15

3

 

0

18

 

 Male

38 (67.9%)

16

22

 

4

34

 

Smoking status

   

0.000

  

0.048

 Smoker

27 (48.2%)

7

20

 

4

23

 

 Non-smoker

29 (51.8%)

24

5

 

0

29

 

Tumour size (cm)

   

0.290

  

0.582

 >3

37 (66.1%)

19

18

 

3

34

 

 ≤3

19 (33.9%)

12

7

 

1

18

 

Stage

   

0.166

  

0.205

 Early (I-II)

24 (42.9%)

11

13

 

3

21

 

 Advanced (III-IV)

32 (57.1%)

20

12

 

1

31

 

Pleural Invasion

   

0.005

  

0.125

 Yes

36 (64.3%)

25

11

 

1

35

 

 No

20 (35.7%)

6

14

 

3

17

 

Node metastasis

   

0.519

  

0.353

 Yes

39 (69.6%)

22

17

 

2

37

 

 No

17 (30.4%)

9

8

 

2

15

 

Lymphovascular invasion

   

0.105

  

0.515

 Yes

34 (60.7%)

21

13

 

2

32

 

 No

22 (39.3%)

10

12

 

2

20

 

Recurrence *

   

0.247

  

0. 492

 Yes

21 (38.9%)

13

8

 

1

20

 

 No

33 (61.1%)

16

17

 

3

30

 

Death **

   

0.167

  

0.674

 Yes

15 (28.8%)

6

9

 

1

14

 

 No

37 (71.2%)

22

15

 

3

34

 
  1. ASC: adenosquamous cell carcinoma.
  2. Note: *Two patients lost to follow-up; **Four patients lost to follow-up.
Back to article page